Heidelberg Pharma, a subsidiary of Wilex, has signed an exclusive multi-target research agreement with Takeda Pharmaceutical Company for the joint development of antibody-drug conjugates that use amanitin as the payload.

Antibody-drug conjugates or ADCs combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer and inflammatory diseases. Antibody Targeted Amanitin Conjugates or ATACs are ADCs whose active ingredient is made up of amatoxin molecules.

Image 1.0: Chemical structure of the amatoxin alpha-amanitin. Courtesy: © 2017 Edgar181, Public domain via Wikimedia Commons

Amatoxins
Amatoxins are small bicyclic peptides (bicyclic octapeptides) naturally occurring in the death cap mushroom (aminita phalloides). Around the world, this mushroom is best known for causing most cases of fatal mushroom poisonings.*

MabPlex
 

Amatoxins are potent and selective inhibitors of RNA polymerase II, a vital enzyme in the synthesis of mRNA, a mechanism that is crucial for the survival of eukaryotic cells, and small nuclear RNA (snRNA). Without mRNA, essential protein synthesis and cell metabolism grind to a halt leading to cell death.

Symptomatically, amatoxins cause necrosis of the liver, also partly in the kidney, with the cellular changes causing the fragmentation and segregation of all nuclear components. [1]

Pre-clinical studies
In pre-clinical testing, ATACs have shown potential advances and be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.  These advances include higher solubility and uniformity due to greater hydrophilicity than other cytotoxic payloads. This, in turn, could further advance the development of therapeutic ADCs.

For example, human epithelial cell adhesion molecules (EpCAM) are overexpressed in many cancers. Anti-EpCAM antibodies have shown promise in pre-clinical studies. However, these antibodies have shown no tumor regression in a number of phase II clinical trial.

In 2012 researchers at the Department of Translational Immunology of the German Cancer Research Center generated an anti-EpCAM antibody conjugates with α-amanitin.  Their pre-clinical results confirmed the potential of an anti-EpCAM antibody conjugates with α-amanitin to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies. [2]

Multi-target research agreement
Under the terms of the exclusive multi-target research agreement, Heidelberg Pharma will produce Antibody Targeted Amanitin Conjugates (ATACs) using antibodies from Takeda’s proprietary portfolio for up to three undisclosed targets.

Takeda has an option for an exclusive license for global development and commercialization rights to each of the product candidates resulting from the research collaboration. If it exercises the option, Takeda would be responsible for further pre-clinical and clinical development, as well as potential commercialization, of any product candidate it licenses.

Photo 1.0: Prof. Dr. Andreas Pahl Chief, Scientific Officer of Wilex and Heidelberg Pharma.

“We are delighted about the collaboration with Takeda, which has broad expertise in oncology and is a leading ADC company,” noted Professor Andreas Pahl, Chief Scientific Officer of Wilex and Heidelberg Pharma.

“We believe this partnership provides further validation of our technology. Working with Takeda will allow us to jointly test and expand the application of the ATAC technology to selected antibodies,” Pahl added.

Exclusive license
Heidelberg Pharma will receive an upfront technology access fee and payments for research services. In the event Takeda exercises its option for an exclusive license, Heidelberg Pharma would receive an option fee. Under the exclusive license agreement, Heidelberg Pharma would be eligible to receive clinical development, regulatory and sales-related milestone payments of up to US $ 113 million for each product candidate, as well as royalties.

The expected financial impact of this partnership is already reflected in Wilex’s financial outlook for the current fiscal year provided in March 2017.

“We see significant potential for Heidelberg Pharma’s ATAC technology, combined with our deep oncology expertise, to develop ADC therapies for patients with unmet medical needs,” said Christopher Arendt, PhD, Head, Oncology DDU & Immunology Unit, Takeda.

“We are excited about this relationship with Heidelberg Pharma, as partnerships such as this one are integral for us to achieve our aspiration of curing cancer,” he concluded.

Takeda signed the agreement with Heidelberg Pharma through its wholly-owned subsidiary, Millennium Pharmaceuticals.


* The lethal dose for humans is estimated at about 0.1mg/kg body weight (approximately 8mg for an 80kg person).